Integrative Assessment of the Diagnostic Significance of the microRNA (-21, -29a, -133a) Panel in Patients With Hypertrophic Cardiomyopathy in Comparison With the Control Group
Open Access
- 11 February 2026
- journal article
- research article
- Published by APO Society of Specialists in Heart Failure in Kardiologiia
- Vol. 66 (1) , 31-37
Abstract
Aim : To evaluate the diagnostic significance of a microRNA panel (-21, -29a, -133a) in patients with hypertrophic cardiomyopathy (HCM) by comparing their expression levels to a group with moderate arterial hypertension (comparison group). Material and methods : A comparative study was conducted involving 80 individuals: 40 patients with confirmed HCM and 40 sex- and age-matched controls (22 men, 18 women, mean age 55.3±13.3 years). All participants underwent a comprehensive examination at the cardiology department, including electrocardiography (ECG), echocardiography with full assessment of intracardiac hemodynamic parameters, Holter ECG monitoring, and laboratory tests. For molecular biological analysis, plasma expression levels of circulating microRNAs (-21, -29a, -133a) were determined for all participants using real-time polymerase chain reaction. Results : Circulating microRNA levels differed significantly between patients with HCM and the comparison group. The analysis showed a significant increase in the microRNA-21 expression (4.07 v s . 2.03; p vs . 1.83; p vs . 6.34; p Conclusion : Increased expression of microRNA-21 and decreased expression of microRNA-29a are associated with myocardial fibrosis, while marked suppression of microRNA-133a reflects hypertrophic remodeling. These findings suggest that this microRNA panel holds promise as potential auxiliary markers for HCM, though clinical significance requires validation in larger, prospective studies.Keywords
This publication has 19 references indexed in Scilit:
- 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic CardiomyopathyJACC, 2020
- Extracellular miRNAs: From Biomarkers to Mediators of Physiology and DiseaseCell Metabolism, 2019
- MicroRNAs distribution in different phenotypes of Aortic StenosisScientific Reports, 2018
- Integrated microRNA and messenger RNA analysis in aortic stenosisScientific Reports, 2016
- Blood-based microRNA signatures differentiate various forms of cardiac hypertrophyInternational Journal of Cardiology, 2015
- Hypertrophic CardiomyopathyJACC, 2014
- Circulating miR-29a, Among Other Up-Regulated MicroRNAs, Is the Only Biomarker for Both Hypertrophy and Fibrosis in Patients With Hypertrophic CardiomyopathyJACC, 2014
- Myocardial and circulating levels of microRNA-21 reflect left ventricular fibrosis in aortic stenosis patientsInternational Journal of Cardiology, 2013
- MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblastsNature, 2008
- MicroRNA-133 controls cardiac hypertrophyNature Medicine, 2007